Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib.
Authors: K K. Wenn, L L. Tomala, S S. Wilop, L L. Vankann, C C. Hasenbank, O O. Frank, A A. Hochhaus, F J FJ. Giles, T T. Lange, M C MC. Müller, S S. Koschmieder, F F. Beier, P P. Ziegler, T H TH. Brümmendorf
Published:
09/15/2015,
Leukemia
PubMed
Full Text